Fig. 1From: Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trialPatient disposition. *Two of the randomized patients withdrew consent after randomization. No safety assessments were performed during the study periodBack to article page